

1. Abu-Shakra M, Mader R, Langevitz, et al. Quality of life in systemic lupus erythematosus: a controlled study. *J Rheumatol*. 1999;26(2):306-309.
2. Alcocer-Varela J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. *J Clin Invest*. 1982;69(6):1388-1392. <http://dx.doi.org/10.1172/JCI110579>.
3. Alarcón GS, Roseman JM, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic groups: II: features predictive of disease activity early in its course. *Arthritis Rheum*. 1998;41:1173-1180. [http://dx.doi.org/10.1002/1529-0131\(199807\)41:7](http://dx.doi.org/10.1002/1529-0131(199807)41:7)
4. Alarcón GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III: a comparison of characteristics early in the natural history of the LUMINA cohort. *Lupus*. 1999;8:197-209. <http://dx.doi.org/10.1191/096120399678847704>.
5. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. *Arthritis Rheum*. 1999;42(9):1785-1796. [http://dx.doi.org/10.1002/1529-0131\(199909\)42:9<1785::AID-ANR1>3.0.CO;2-#](http://dx.doi.org/10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#).
6. Bengtsson A, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. *Lupus*. 2000;9(9):664-671. <http://dx.doi.org/10.1191/096120300674499064>.
7. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. *Arthritis Rheum*. 2006;54(8):2550-2557. <http://dx.doi.org/10.1002/art.21955>.
8. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. *Ann Rheum Dis*. 2008;67(2):195-205. <http://dx.doi.org/10.1136/ard.2007.070367>.
9. Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare [published online ahead of print July 6, 2010]. *Lupus*. 2010;19(11):1272-1280. <http://dx.doi.org/10.1177/0961203310371154>.
10. Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of twins with systemic lupus erythematosus: a review of the literature and presentation of 12 additional sets. *Am J Med*. 1975;59(4):533-52. [http://dx.doi.org/10.1016/0002-9343\(75\)90261-2](http://dx.doi.org/10.1016/0002-9343(75)90261-2).
11. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients: the Committee on Prognosis Studies in SLE. *Arthritis Rheum*. 1992;35(6):630-640. <http://dx.doi.org/10.1002/art.1780350606>.
12. Brennan D, Yui M, Wuthrich R, Kelley V. Tumor necrosis factor and IL-1 in New Zealand Black/White mice: enhanced gene expression and acceleration of renal injury. *J Immunol*. 1989;143(11):3470-3475.
13. Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. *J Rheumatol*. 1993;20:977-981.
14. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med*. 2005;142(12, pt 1):953-962.
15. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. *Br Med J (Clin Res Ed)*. 1984;289(6442):410-412. <http://dx.doi.org/10.1136/bmj.289.6442.410>.

16. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. *J Occup Environ Med.* 2009;51(1):66-79. <http://dx.doi.org/10.1097/JOM.0b013e31818a405a>.
17. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore).* 2003;82(5):299-308. <http://dx.doi.org/10.1097/01.md.0000091181.93122.55>.
18. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients: the European Working Party on Systemic Lupus Erythematosus. *Medicine (Baltimore).* 1993;72(2):113-124.
19. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. *Arthritis Rheum.* 2007;56(6):2092-2094. <http://dx.doi.org/10.1002/art.22641>.
20. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. *Rheumatol. (Oxford).* 2009;48(6):673-675. <http://dx.doi.org/10.1093/rheumatology/kep062>.
21. Clarke AE, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. *Rheumatol. (Oxford).* 2004;43(8):1016-1024. <http://dx.doi.org/10.1093/rheumatology/keh229>.
22. Costner MI, Sontheimer RD. Lupus erythematosus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. *Fitzpatrick's Dermatology in General Medicine.* 7th ed. New York: McGraw-Hill; 2008. <http://www.accessmedicine.com/content.aspx?aID=2991998>. Accessed January 10, 2012.
23. Crispín JC, Liossis SN, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol Med.* 2010;16(2):47-57. <http://dx.doi.org/10.1016/j.molmed.2009.12.005>.
24. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. *Rheumatol. (Oxford).* 2011;50(8):1424-1430. <http://dx.doi.org/10.1093/rheumatology/ker101>.
25. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. *Lancet.* 2007;369(9561):587-596. [http://dx.doi.org/10.1016/S0140-6736\(07\)60279-7](http://dx.doi.org/10.1016/S0140-6736(07)60279-7).
26. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. *Arthritis Rheum.* 1992;35(3):311-318. <http://dx.doi.org/10.1002/art.1780350310>.
27. Delafuente JC, Cappuzzo KA. Systemic lupus erythematosus and other collagen-vascular diseases. In: Dipiro JT, Talbert R, Yee GC, et al, eds. *Pharmacotherapy.* 7th ed. New York, NY: McGraw-Hill; 2008:1431-1445.
28. Edwards C, Zhou T, Zhang J, et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF- α . *J Immunol.* 1996;157(4):1758-1772.
29. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum.* 2001;44(10):2331-2337.

30. Faurischou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. *J Rheumatol*. 2006;33(8):1563-1569.
31. Fernando MM, Isenberg DA. How to monitor SLE in routine clinical practice. *Ann Rheum Dis*. 2005;64(4):524-527. <http://dx.doi.org/10.1136/ard.2003.015248>.
32. Fessel WJ. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms: the high prevalence in black women. *Arch Intern Med*. 1974;134:1027-1035. <http://dx.doi.org/10.1001/archinte.1974.00320240061006>.
33. Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. *Semin Arthritis Rheum*. 2004;33(4):217-230. [http://dx.doi.org/10.1053/S0049-0172\(03\)00133-1](http://dx.doi.org/10.1053/S0049-0172(03)00133-1).
34. Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. *Lab Invest*. 1993;69:494-507.
35. Freni-Titulaer LW, Kelley DB, Grow AG, et al. Connective tissue disease in southeastern Georgia: a case-control study of etiologic factors. *Am J Epidemiol*. 1989;130:404-409.
36. Fritzler MJ, Tan EM. Antibodies to histones in drug-induced and idiopathic lupus erythematosus. *J Clin Invest*. 1978;62(3):560-567. <http://dx.doi.org/10.1172/JCI109161>.
37. Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. *J Rheumatol*. 1999;26:1694-1700.
38. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum*. 1996;39(3):363-369. <http://dx.doi.org/10.1002/art.1780390303>.
39. Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. *J Rheumatol*. 1992;19(4):608-611.
40. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. *Best Pract Res Clin Rheumatol*. 2005;19(5):685-708. <http://dx.doi.org/10.1016/j.berh.2005.03.010>.
41. Grigor R, Edmonds J, Lewkonja R, Bresnihan B, Hughes GR. Systemic lupus erythematosus: a prospective analysis. *Ann Rheum Dis*. 1978;37(2):121-128. <http://dx.doi.org/10.1136/ard.37.2.121>.
42. Gross J, Dillon S, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BlyS. *Immunity*. 2001;15(2):289-302. [http://dx.doi.org/10.1016/S1074-7613\(01\)00183-2](http://dx.doi.org/10.1016/S1074-7613(01)00183-2).
43. Hahn BH. Systemic lupus erythematosus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*. 18th ed. New York: McGraw-Hill; 2012. <http://www.accessmedicine.com/content.aspx?aID=9136499>. Accessed January 10, 2012.
44. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. *Q J Med*. 1993;86(7):447-458.
45. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. *Arthritis Rheum*. 2008;58(1):15-25. <http://dx.doi.org/10.1002/art.23177>.

46. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. *Arthritis Rheum.* 1985;28(1):80-86.
47. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. *Ann Rheum Dis.* 1994;53(10):675-680. <http://dx.doi.org/10.1136/ard.53.10.675>.
48. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus [published online ahead of print April 6, 2005]. *Rheumatol. (Oxford).* 2005;44(7):902-906. <http://dx.doi.org/10.1093/rheumatology/keh624>.
49. Jacob C, McDevitt H. Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis. *Nature.* 1988;331(6154):356-358. <http://dx.doi.org/10.1038/331356a0>.
50. James JA, Gross T, Scofield RH, et al. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. *J Exp Med.* 1995;181:453-461. <http://dx.doi.org/10.1084/jem.181.2.453>.
51. Järvinen P, Kaprio J, Mäkitalo R, Koskenvuo M, Aho K. Systemic lupus erythematosus and related systemic diseases in a nationwide twin cohort: an increased prevalence of disease in MZ twins and concordance of disease features. *J Intern Med.* 1992;231(1):67-72. <http://dx.doi.org/10.1111/j.1365-2796.1992.tb00500.x>.
52. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? *J Rheumatol.* 2005;32(9):1706-1708.
53. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. *J Rheumatol.* 2005;32(9):1699-1705.
54. Kakati S, Doley B, Pal S, Deka UJ. Pulmonary manifestations in systemic lupus erythematosus (SLE) with special reference to HR CT. *J Assoc Physicians India.* 2007;55:839-841.
55. Kavanaugh AF, Solomon DH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. *Arthritis Rheum.* 2002;47(5):546-555. <http://dx.doi.org/10.1002/art.10558>.
56. Kim WU, Min SY, Hwang SH, Yoo SA, Kim KJ, Cho CS. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. *Clin Exp Immunol.* 2010;161(3):453-458. <http://dx.doi.org/10.1111/j.1365-2249.2010.04194.x>.
57. Klinman DM. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. *J Clin Invest.* 1990;86(4):1249-1254.
58. Klinman DM, Shirai A, Ishigatsubo Y, et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. *Arthritis Rheum.* 1991;34:1404-1410. <http://dx.doi.org/10.1002/art.1780341110>.
59. Kono DH, Burlingame RW, Owens DG, et al. Lupus susceptibility loci in New Zealand mice. *Proc Natl Acad Sci USA.* 1994;91(21):10168-10172. <http://dx.doi.org/10.1073/pnas.91.21.10168>.
60. La Cava A. Anticytokine therapies in systemic lupus erythematosus. *Immunotherapy.* 2010;2(4):575-582. <http://dx.doi.org/10.2217/imt.10.29>.

61. Lau CS, Mak A. The socioeconomic burden of SLE. *Nat Rev Rheumatol*. 2009;5(7):400-404. <http://dx.doi.org/10.1038/nrrheum.2009.106>.
62. Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. *J Biomed Biotechnol*. 2010;2010:676284. <http://dx.doi.org/10.1155/2010/676284>.
63. Leonhardt ET. Family studies in systemic lupus erythematosus. *Clin Exp Immunol*. 1967;2(suppl):743-759.
64. Levinson W. Cellular basis of the immune response. In: Levinson W, ed. *Review of Medical Microbiology and Immunology*. 11th ed. New York: McGraw-Hill; 2010.
65. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. *J Immunol*. 1991;147:117-123.
66. Linker-Israeli M, Bakke AC, Kitridou RC, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). *J Immunol*. 1983;130:2651-2655.
67. Liu CC, Ahearn JM. The search for lupus biomarkers. *Best Pract Res Clin Rheumatol*. 2009;23(4):507-523. <http://dx.doi.org/10.1016/j.berh.2009.01.008>.
68. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort [published online ahead of print November 21, 2011]. *Rheumatology (Oxford)*. <http://dx.doi.org/10.1093/rheumatology/ker368>.
69. Lupus Foundation of America. Forms of lupus. Lupus Foundation of America website. <http://www.lupus.org/webmodules/webarticlesnet/templates/default.aspx?a=2234&template=print-article.htm>. Accessed November 1, 2011.
70. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. *Lupus*. 1993;2(2):115-118. <http://dx.doi.org/10.1177/096120339300200209>.
71. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. *Am J Epidemiol*. 1997;145(5):408-415.
72. Manzi S. Epidemiology of systemic lupus erythematosus. *Am J Manag Care*. 2001;7(16)(suppl):S474-S479.
73. Manzi S. Lupus update: perspective and clinical pearls. *Cleve Clin J Med*. 2009;76(2):137-142. <http://dx.doi.org/10.3949/ccjm.76a.gr005>.
74. Mayeaux E Jr. Lupus erythematosus (systemic and cutaneous). In: Usatine RP, Smith MA, Chumley H, Mayeaux, E Jr, Tysinger J, eds. *The Color Atlas of Family Medicine*. New York: McGraw-Hill; 2009. <http://www.accessmedicine.com/content.aspx?aID=8208514>. Accessed January 10, 2012.
75. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwok CK. Incidence of systemic lupus erythematosus: race and gender differences. *Arthritis Rheum*. 1995;38(9):1260-1270. <http://dx.doi.org/10.1002/art.1780380914>.
76. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. *Mayo Clin Proc*. 1985;60(2):105-113.
77. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. *Arthritis Rheum*. 1999;42(6):1274-1280. [http://dx.doi.org/10.1002/1529-0131\(199906\)42:6<1274::AID-ANR26>3.0.CO;2-B](http://dx.doi.org/10.1002/1529-0131(199906)42:6<1274::AID-ANR26>3.0.CO;2-B).

78. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. *J Clin Pathol*. 2003;56(7):481-490. <http://dx.doi.org/10.1136/jcp.56.7.481>.
79. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. *Ann Rheum Dis*. 2010;69(7):1269-1274. <http://dx.doi.org/10.1136/ard.2009.117200>.
80. Narain S, Richards HB, Satoh M, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. *Arch Intern Med*. 2004;164(22):2435-2241. <http://dx.doi.org/10.1001/archinte.164.22.2435>.
81. National Institutes of Health. http://report.nih.gov/biennialreport0607/research_activities_by_disease_categories/autoimmune_diseases.aspx?SID=24. Accessed July 6, 2012.
82. Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ. Contribution of renal biopsy data in predicting outcome in lupus nephritis: analysis of 116 patients. *Arthritis Rheum*. 1990;33(7):970-977. <http://dx.doi.org/10.1002/art.1780330708>.
83. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. *Lupus*. 2007;16(5):309-317. <http://dx.doi.org/10.1177/0961203307077987>.
84. Ozbek S, Sert M, Paydas S, Soy M. Delay in the diagnosis of SLE: the importance of arthritis/arthritis as the initial symptom. *Acta Med Okayama*. 2003;57(4):187-190.
85. Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. *Arthritis Rheum*. 2007;57(1):64-70. <http://dx.doi.org/10.1002/art.22470>.
86. Pelton BK, Hylton W, Denman AM. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. *Clin Exp Immunol*. 1992;89(2):251-254. <http://dx.doi.org/10.1111/j.1365-2249.1992.tb06940.x>.
87. Perdriger A, Werner-Leyval S, Rollot-Elamrani K. The genetic basis for systemic lupus erythematosus. *Joint Bone Spine*. 2003;70(2):103-108. [http://dx.doi.org/10.1016/S1297-319X\(03\)00007-1](http://dx.doi.org/10.1016/S1297-319X(03)00007-1).
88. Perez-Gutthann S, Petri M, Hochberg MC. Comparison of different methods of classifying patients with systemic lupus erythematosus. *J Rheumatol*. 1991;18:1176-1179.
89. Petri M, Kim MY, Kalunian KC, et al; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med*. 2005;353(24):2550-2558. <http://dx.doi.org/10.1056/NEJMoa051135>.
90. Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. *Semin Arthritis Rheum*. 1984;13:349-359.
91. Ramsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures. *Arthritis Care Res*. 2003;49:S225-S233. <http://dx.doi.org/10.1002/art.11402>.
92. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. *Nat Rev Rheumatol*. 2010;6:339-347.
93. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. *Q J Med*. 1985;55(216):87-98.
94. Rus V, Maury EE, Hochberg MC. Epidemiology of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus*. 7th ed. Philadelphia, PA:

- Lippincott Williams & Wilkins; 2007:34-44. <http://dx.doi.org/10.1016/B978-0-323-04434-9.50017-8>.
95. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. *J Clin Invest*. 1996;97:1348-1354. <http://dx.doi.org/10.1172/JCI118552>.
 96. Samanta A, Roy S, Feehally J, Symmons DP. The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK. *Br J Rheumatol*. 1992;31(10):679-682. <http://dx.doi.org/10.1093/rheumatology/31.10.679>.
 97. Schur PH. Genetics of systemic lupus erythematosus. *Lupus*. 1995;4(6):425-437. <http://dx.doi.org/10.1177/096120339500400603>.
 98. Sequeira JF, et al. Systemic lupus erythematosus: sex hormones in male patients. *Lupus*. 1993;2:315-317.
 99. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. *Semin Arthritis Rheum*. 1973;3(1):1-54. [http://dx.doi.org/10.1016/0049-0172\(73\)90034-6](http://dx.doi.org/10.1016/0049-0172(73)90034-6).
 100. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. *J Rheumatol*. 1989;16:918-925.
 101. Slawsky KA, Fernandes AW, Furfeld L, Manzi S, Goss TF. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. *Arthritis Care Res (Hoboken)*. 2011;63(9):1224-1232. <http://dx.doi.org/10.1002/acr.20502>.
 102. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Clin J Am Soc Nephrol*. 2010;5(11):2060-2088. <http://dx.doi.org/10.2215/CJN.00240110>.
 103. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. *Arthritis Rheum*. 2002;47(4):434-444. <http://dx.doi.org/10.1002/art.10561>.
 104. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. *Rheumatol (Oxford)*. 2004;43(8):1039-1044. <http://dx.doi.org/10.1093/rheumatology/keh238>.
 105. Sutcliffe N, Stoll T, Pyke S, Isenberg D. Functional disability and end organ damage in patients with SLE, SLE and Sjogren's syndrome and primary SS. *J Rheumatol*. 1998;25:63-68.
 106. Tan E, Cohen A, Fries J, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1982;25:1271-1277.
 107. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. *J Rheumatol*. 2002;29(2):282-287.
 108. Taylor HG, Stein CM. Systemic lupus erythematosus in Zimbabwe. *Ann Rheum Dis*. 1986;45(8):645-648.
 109. Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. *Immunol Rev*. 1981;55:179-216. <http://dx.doi.org/10.1111/j.1600-065X.1981.tb00343.x>.
 110. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. *Lupus*. 2010;19:49-51. <http://dx.doi.org/10.1177/0961203309346505>.

111. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. *Arthritis Rheum.* 1999;42(1):46-50. [http://dx.doi.org/10.1002/1529-0131\(199901\)42:1<46::AID-ANR6>3.0.CO; -2](http://dx.doi.org/10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO; -2).
112. Uribe AG, McGwin G Jr, Reveille JD, Alarcón GS. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? where are we heading? *Autoimmun Rev.* 2004;3(4):321-329. <http://dx.doi.org/10.1016/j.autrev.2003.11.005>.
113. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. *Am J Med.* 1976;60(2):221-225. [http://dx.doi.org/10.1016/0002-9343\(76\)90431-9](http://dx.doi.org/10.1016/0002-9343(76)90431-9).
114. Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. *Arthritis Care Res (Hoboken).* 2012;64(1):132-137. <http://dx.doi.org/10.1002/acr.20648>.
115. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. *J Rheumatol.* 2001;28(3):525-532.
116. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. *J Womens Health (Larchmt).* 2004;13(6):713-718. <http://dx.doi.org/10.1089/jwh.2004.13.713>.
117. Warrington RJ. Interleukin-2 abnormalities in systemic lupus erythematosus and rheumatoid arthritis: a role for overproduction of interleukin-2 in human autoimmunity? *J Rheumatol.* 1988;15:616-620.
118. Weinstein A, Bordwell B, Stone B, Tibbetts C, Rothfield NF. Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. *Am J Med.* 1983;174:206-216. [http://dx.doi.org/10.1016/0002-9343\(83\)90613-7](http://dx.doi.org/10.1016/0002-9343(83)90613-7).
119. Winchester RJ. Genetic aspects. In: Schur PH, ed. *Clinical Management of Systemic Lupus Erythematosus*. New York, NY: Grune & Stratton; 1983:17-27.
120. Wollaston SJ, Farewell VT, Isenberg DA, et al; Systemic Lupus International Collaborating Clinics (SLICC). Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. *J Rheumatol.* 2004;31(12):2390-2394.
121. Yancey KB, Lawley TJ. Immunologically mediated skin diseases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*. 18th ed. New York: McGraw-Hill; 2012. <http://www.accessmedicine.com/content.aspx?aID=9098448>. Accessed January 10, 2012.
122. Yelin E, Trupin L, Katz P, et al. Work dynamics among persons with systemic lupus erythematosus. *Arthritis Rheum.* 2007;57(1):56-63. <http://dx.doi.org/10.1002/art.22481>.
123. Zabaleta-Lanz M, Vargas-Arenas RE, et al. Silent nephritis in systemic lupus erythematosus. *Lupus.* 2003;12(1):26-30. <http://dx.doi.org/10.1191/0961203303lu259oa>.
124. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. *Arthritis Rheum.* 2009;61(9):1159-1167. <http://dx.doi.org/10.1002/art.24725>.